AI Insight
This review examines mRNA vaccine technology, which has demonstrated rapid development capabilities, scalable production, and strong immune responses with favorable safety outcomes. The COVID-19 pandemic enabled unprecedented real-world assessment through billions of doses administered globally across diverse populations. The analysis covers mechanistic understanding, preclinical and clinical evidence, and public health data to evaluate both safety and efficacy of the mRNA vaccine platform.
Why it matters
The findings validate mRNA vaccines as a viable platform for future vaccine development against emerging infectious diseases and potentially other medical applications. The extensive safety and efficacy data gathered from global deployment provides critical evidence for regulatory decisions and public health policy regarding this transformative vaccine technology.
Understand the Science
mRNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing, and strong immunogenicity with a favourable safety profile. Global deployment of mRNA vaccines during the COVID-19 pandemic provided an unprecedented real-world evaluation of this platform, with billions of doses administered across diverse populations. In this Review, we critically examine the safety and efficacy of mRNA vaccines from mechanistic, preclinical, clinical, and public health perspectives.
Source: [Review] Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective